BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease. Journal of Crohn's and Colitis 2010;4:603-5. [DOI: 10.1016/j.crohns.2010.05.001] [Cited by in Crossref: 229] [Cited by in F6Publishing: 182] [Article Influence: 20.8] [Reference Citation Analysis]
Number Citing Articles
1 Kanis SL, de Lima-Karagiannis A, van der Ent C, Rizopoulos D, van der Woude CJ. Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. J Crohns Colitis 2018;12:939-47. [PMID: 29771301 DOI: 10.1093/ecco-jcc/jjy058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
2 Pottinger E, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol 2018;178:95-102. [PMID: 28718898 DOI: 10.1111/bjd.15802] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
3 Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, Högenauer C, Koch R, Hermann J, Studnicka-Benke A, Weger W, Puchner R, Dejaco C. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019;131:29-44. [PMID: 30643992 DOI: 10.1007/s00508-019-1448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
4 Palosse-Cantaloube L, Hurault-Delarue C, Beau AB, Montastruc JL, Lacroix I, Damase-Michel C. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity: A population-based cohort study. Pharmacol Res 2016;113:557-62. [PMID: 27697641 DOI: 10.1016/j.phrs.2016.09.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:985-1002. [PMID: 21936033 DOI: 10.1002/ibd.21871] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
6 Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016;8:23-36. [PMID: 27843367 DOI: 10.2147/OARRR.S85340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
7 Berman M, Zisman D, Wollman J, Levartovsky D, Rimon E, Elkayam O, Paran D. The Effect of Pregnancy on Disease Activity in Patients with Psoriatic Arthritis. J Rheumatol 2018;45:1651-5. [PMID: 30219770 DOI: 10.3899/jrheum.171218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
8 Grotting LA, Papaliodis GN. A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy. Semin Ophthalmol 2017;32:75-81. [PMID: 27805464 DOI: 10.1080/08820538.2016.1228402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
10 Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958. [PMID: 23834232 DOI: 10.3109/00365521.2013.812141] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
11 Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med 2021;14:4-11. [PMID: 33995565 DOI: 10.1177/1753495X20919214] [Reference Citation Analysis]
12 Luu M, Benzenine E, Barkun A, Doret M, Michiels C, Degand T, Quantin C, Bardou M. Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort. Aliment Pharmacol Ther 2019;50:1181-8. [PMID: 31617226 DOI: 10.1111/apt.15504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
13 van der Woude CJ, Kolacek S, Dotan I, Øresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A; for the European Crohn's Colitis Organisation (ECCO). European evidenced-based consensus on reproduction in inflammatory bowel disease. Journal of Crohn's and Colitis 2010;4:493-510. [DOI: 10.1016/j.crohns.2010.07.004] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 10.3] [Reference Citation Analysis]
14 Seow CH, Nguyen GC. “Just in Time”: When Is It Safe to Administer Live Vaccines to Infants Exposed to Anti-Tumor Necrosis Factor Agents In Utero? Gastroenterology 2016;151:1249-50. [DOI: 10.1053/j.gastro.2016.05.061] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
15 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
16 Brown SM, Aljefri K, Waas R, Hampton P. Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid. J Dermatolog Treat 2019;30:2-18. [PMID: 28092212 DOI: 10.1080/09546634.2016.1202402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA. Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study. Arthritis Care Res 2018;70:979-86. [DOI: 10.1002/acr.23434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
18 Nielsen OH, Bjerrum JT, Seidelin JB, Nyberg C, Ainsworth M. Biological treatment of Crohn’s disease. Dig Dis. 2012;30 Suppl 3:121-133. [PMID: 23295703 DOI: 10.1159/000342738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 Smeele HTW, Dolhain RJEM. Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Semin Arthritis Rheum 2019;49:S32-5. [PMID: 31779849 DOI: 10.1016/j.semarthrit.2019.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
20 De Felice KM, Kane SV. Inflammatory bowel disease in women of reproductive age. Expert Rev Gastroenterol Hepatol 2014;8:417-25. [PMID: 24580047 DOI: 10.1586/17474124.2014.893822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
21 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
22 Tsao NW, Lynd LD, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA. Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study. BMJ Open 2019;9:e023714. [PMID: 30787081 DOI: 10.1136/bmjopen-2018-023714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
23 Hosseini-Carroll P, Mutyala M, Seth A, Nageeb S, Soliman D, Boktor M, Sheth A, Chapman J, Morris J, Jordan P. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther. 2015;6:156-171. [PMID: 26558150 DOI: 10.4292/wjgpt.v6.i4.156] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
24 Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 2018;11:987-98. [PMID: 30227748 DOI: 10.1080/17512433.2018.1525293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
25 Foulon A, Chevreau J, Yzet C, Gondry J, Fumery M. [IBD and pregnancy: From conception to birth]. Gynecol Obstet Fertil Senol 2020;48:514-9. [PMID: 32145453 DOI: 10.1016/j.gofs.2020.02.013] [Reference Citation Analysis]
26 Yamamoto Y, Aoki S. Systemic lupus erythematosus: strategies to improve pregnancy outcomes. Int J Womens Health 2016;8:265-72. [PMID: 27468250 DOI: 10.2147/IJWH.S90157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
27 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
28 Laube R, Paramsothy S, Leong RW. Review of pregnancy in Crohn's disease and ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211016242. [PMID: 34046084 DOI: 10.1177/17562848211016242] [Reference Citation Analysis]
29 Johnsson A, Avlund S, Grosen A, Julsgaard M. Chicken pox infection in a three months old infant exposed in utero to Adalimumab. Journal of Crohn's and Colitis 2013;7:e116-7. [DOI: 10.1016/j.crohns.2012.07.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
30 Ellinger I, Fuchs R. HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn. Wien Med Wochenschr 2012;162:207-13. [PMID: 22717875 DOI: 10.1007/s10354-012-0085-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
31 De Simone C, Caldarola G, Moretta G, Piscitelli L, Ricceri F, Prignano F. Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereol 2019;154:305-14. [PMID: 31001966 DOI: 10.23736/S0392-0488.18.06255-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
32 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 2019;80:43-53. [DOI: 10.1016/j.jaad.2018.06.056] [Cited by in Crossref: 119] [Cited by in F6Publishing: 83] [Article Influence: 59.5] [Reference Citation Analysis]
33 Lobo Y, Lee RC, Spelman L. Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature. Case Rep Dermatol 2021;13:248-56. [PMID: 34177514 DOI: 10.1159/000515246] [Reference Citation Analysis]
34 Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10-27. [PMID: 28381345 DOI: 10.1016/j.jaut.2017.03.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 17.3] [Reference Citation Analysis]
35 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
36 van der Zwan M, Baan CC, van Gelder T, Hesselink DA. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. Clin Pharmacokinet 2018;57:191-207. [PMID: 28669130 DOI: 10.1007/s40262-017-0573-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
37 Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Review of Clinical Immunology 2016;12:937-44. [DOI: 10.1080/1744666x.2016.1184973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
38 Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 2017;10:661-9. [PMID: 28326845 DOI: 10.1080/17512433.2017.1305268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
39 Armuzzi A, Bortoli A, Castiglione F, Contaldo A, Daperno M, D'Incà R, Labarile N, Mazzuoli S, Onali S, Milla M, Orlando A, Principi M, Pugliese D, Renna S, Rizzello F, Scribano ML, Todeschini A; Italian Group for the Study of Inflammatory Bowel Disease Working Group. Female reproductive health and inflammatory bowel disease: A practice-based review. Dig Liver Dis 2021:S1590-8658(21)00271-1. [PMID: 34120858 DOI: 10.1016/j.dld.2021.05.020] [Reference Citation Analysis]
40 Selinger CP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective. World J Gastroenterol 2012;18:2600-8. [PMID: 22690068 DOI: 10.3748/wjg.v18.i21.2600] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
41 van der Woude CJ, Kanis SL. IBD: Exposure to anti-TNF agents in utero: controlling health risks. Nat Rev Gastroenterol Hepatol 2016;13:387-8. [PMID: 27251210 DOI: 10.1038/nrgastro.2016.94] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
42 Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013;9:161-173; quiz 174. [PMID: 23390947 DOI: 10.1586/eci.12.103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
43 Sekaran A, Borum ML. Pregnant inflammatory bowel disease patients may require counselling regarding live vaccines in newborns. World J Gastroenterol 2014;20:11927-8. [PMID: 25206302 DOI: 10.3748/wjg.v20.i33.11927] [Reference Citation Analysis]
44 Ostensen M, Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011;23:293-298. [PMID: 21346578 DOI: 10.1097/bor.0b013e328344a732] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
45 Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, Bossios A, Boyman O, Chaker A, Chan S, Chatzipetrou A, du Toit G, Jutel M, Kauppi P, Kolios A, Li C, Matucci A, Marson A, Bendien S, Palomares O, Rogala B, Szepfalusi Z, Untersmayr E, Vultaggio A, Eiwegger T. Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy 2021;76:71-89. [PMID: 32189356 DOI: 10.1111/all.14282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
46 Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Seminars in Arthritis and Rheumatism 2017;47:29-37. [DOI: 10.1016/j.semarthrit.2017.02.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
47 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
48 Julsgaard M, Hvas CL, Christensen LA, Bell SJ. Reply. Gastroenterology 2016;151:1250-1. [DOI: 10.1053/j.gastro.2016.10.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Gubatan J, Nielsen OH, Levitte S, Juhl CB, Maxwell C, Streett SE, Habtezion A. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2021;116:243-53. [PMID: 33110017 DOI: 10.14309/ajg.0000000000000910] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
50 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
51 Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J, Torrente-Segarra V, Sánchez-Manubens J, Giménez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A; Carmen García de Vicuña Muñoz de la Nava. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study. Pediatr Rheumatol Online J 2015;13:54. [PMID: 26635208 DOI: 10.1186/s12969-015-0054-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
52 Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318-321. [PMID: 23103819 DOI: 10.1016/j.cgh.2012.10.024] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 10.2] [Reference Citation Analysis]
53 De Lorenzo R, Ramirez GA, Punzo D, Lorioli L, Rovelli R, Canti V, Barera G, Rovere-Querini P. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol Res 2020;152:104583. [PMID: 31816434 DOI: 10.1016/j.phrs.2019.104583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Shimada S, Matsuoka D, Murase T, Hachiya A, Motoki N, Nakazawa Y. Impact of infliximab administration before plasma exchange therapy on patients with Kawasaki disease. Ther Apher Dial 2020;24:718-24. [PMID: 32077249 DOI: 10.1111/1744-9987.13486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
55 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol 2018;16:99-105. [PMID: 28870657 DOI: 10.1016/j.cgh.2017.08.041] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
57 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012;35:501-515. [PMID: 22221203 DOI: 10.1111/j.1365-2036.2011.04967.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
59 Yoshida M, Takeuchi I, Shoji K, Miyairi I, Arai K. Bacillus Calmette-Guérin Cervical Lymphadenitis in a 6-Year-Old Boy on Infliximab for Inflammatory Bowel Disease. Pediatr Infect Dis J 2020;39:e242-4. [PMID: 32345827 DOI: 10.1097/INF.0000000000002712] [Reference Citation Analysis]
60 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
61 Martínez López JA, García Vivar ML, Cáliz R, Freire M, Galindo M, Hernández MV, López Longo FJ, Martínez Taboada V, Pego Reigosa JM, Rubio E, Trujillo E, Vela-Casasempere P. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding. Reumatol Clin 2017;13:264-81. [PMID: 27321859 DOI: 10.1016/j.reuma.2016.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
62 Aggarwal R, Ranganathan P. Study designs: Part 2 - Descriptive studies. Perspect Clin Res 2019;10:34-6. [PMID: 30834206 DOI: 10.4103/picr.PICR_154_18] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
63 Long MD, Gulati A, Wohl D, Herfarth H. Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach. Inflamm Bowel Dis 2015;21:1993-2003. [PMID: 25966839 DOI: 10.1097/MIB.0000000000000395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
64 De Vroey B, Colombel J. Optimizing treatment and minimizing adverse events. Nat Rev Gastroenterol Hepatol 2011;8:74-6. [DOI: 10.1038/nrgastro.2010.218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
65 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
66 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol 2015;60:575-89. [PMID: 26164735 DOI: 10.1016/j.survophthal.2015.06.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 9.5] [Reference Citation Analysis]
67 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
68 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 178] [Article Influence: 37.3] [Reference Citation Analysis]
69 Sagami S, Kobayashi T, Hibi T. Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. Inflamm Intest Dis 2018;3:1-10. [PMID: 30505836 DOI: 10.1159/000489643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Simonetti O, Rizzetto G, Molinelli E, Diotallevi F, Radi G, Cirioni O, D'Errico MM, Offidani A. Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting. Healthcare (Basel) 2021;9:401. [PMID: 33916122 DOI: 10.3390/healthcare9040401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Birru Talabi M, Clowse MEB. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol. 2020;32:238-246. [PMID: 32205567 DOI: 10.1097/bor.0000000000000710] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
72 Mahadevan U, Mcconnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology 2017;152:451-462.e2. [DOI: 10.1053/j.gastro.2016.10.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
73 Zelinkova Z, de Haar C, de Ridder L, Pierik MJ, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-1058. [PMID: 21366638 DOI: 10.1111/j.1365-2036.2011.04617.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 13.2] [Reference Citation Analysis]
74 Babuna Kobaner G, Polat Ekinci A. Use of biologic therapies for psoriasis during pregnancy and long-term outcomes of exposed children: A 14-year real-life experience at a tertiary center in Turkey and review of the literature. Dermatol Ther 2020;33:e14420. [PMID: 33068029 DOI: 10.1111/dth.14420] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 El Miedany Y, Palmer D. Rheumatology-led pregnancy clinic: enhancing the care of women with rheumatic diseases during pregnancy. Clin Rheumatol 2020;39:3593-601. [PMID: 32495228 DOI: 10.1007/s10067-020-05173-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
76 Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO. A Case of Crohn's Disease Having Normal Delivery after Infliximab Treatment during Early Pregnancy. Korean J Gastroenterol 2013;61:37. [DOI: 10.4166/kjg.2013.61.1.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Steenholdt C, Al-Khalaf M, Ainsworth MA, Brynskov J. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis. 2012;6:358-361. [PMID: 22405174 DOI: 10.1016/j.crohns.2011.10.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
78 Furer V, Rondaan C, Heijstek MW, Agmon-levin N, van Assen S, Bijl M, Breedveld FC, D'amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2019;79:39-52. [DOI: 10.1136/annrheumdis-2019-215882] [Cited by in Crossref: 193] [Cited by in F6Publishing: 118] [Article Influence: 96.5] [Reference Citation Analysis]
79 Ince-Askan H, Dolhain RJ. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:580-96. [PMID: 26697768 DOI: 10.1016/j.berh.2015.07.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
80 Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine 2014;32:3725-31. [DOI: 10.1016/j.vaccine.2014.05.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
81 Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21-5. [PMID: 28492050 DOI: 10.1016/j.ijwd.2016.12.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
82 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Duricova D, Mitrova K. Editorial: safety of prenatal exposure to anti-TNF therapy on postnatal infectious complications. Aliment Pharmacol Ther 2020;52:1216-7. [PMID: 33016561 DOI: 10.1111/apt.16029] [Reference Citation Analysis]
84 Østensen M. Antirheumatic biologics in pregnant patients: a call for studies to address the knowledge gap. Expert Review of Clinical Immunology 2018;14:95-7. [DOI: 10.1080/1744666x.2018.1423963] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Berkhout A, Clark JE, Wen SC. In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration. Expert Rev Vaccines 2019;18:495-504. [PMID: 30916600 DOI: 10.1080/14760584.2019.1599286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
86 Lee CK. [Ideal vaccination strategy in inflammatory bowel disease]. Korean J Gastroenterol 2015;65:159-64. [PMID: 25797379 DOI: 10.4166/kjg.2015.65.3.159] [Reference Citation Analysis]
87 Guerrero Vinsard D, Kane SV. Biologics and pregnancy: a clinician's guide to the management of IBD in pregnant women. Expert Rev Gastroenterol Hepatol 2021;15:633-41. [PMID: 33440996 DOI: 10.1080/17474124.2021.1876562] [Reference Citation Analysis]
88 Soh MC, Moretto M. The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy. Obstet Med 2020;13:5-13. [PMID: 32284726 DOI: 10.1177/1753495X19841799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Damas OM, Deshpande AR, Avalos DJ, Abreu MT. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today. J Crohns Colitis. 2015;9:928-936. [PMID: 26129693 DOI: 10.1093/ecco-jcc/jjv118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
90 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
91 Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation. Journal of the American Academy of Dermatology 2014;70:401.e1-401.e14. [DOI: 10.1016/j.jaad.2013.09.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
92 Carlucci JG, Halasa N, Creech CB, Dulek DE, Gómez-Duarte OG, Nelson GE, Talbot HK, Scalise ML, Scott PL, Mahadevan U, Beaulieu DB. Vertical Transmission of Histoplasmosis Associated With Anti-Tumor Necrosis Factor Therapy. J Pediatric Infect Dis Soc 2016;5:e9-e12. [PMID: 27012275 DOI: 10.1093/jpids/piw001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
93 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
94 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 144] [Article Influence: 61.3] [Reference Citation Analysis]
95 Dipasquale V, Romano C. Pharmacological treatments and infectious diseases in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2018;12:237-47. [PMID: 28994306 DOI: 10.1080/17474124.2018.1391091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Grunewald S, Staubach P. Dermatologische topische und Systemtherapie in der Schwangerschaft. Hautarzt 2017;68:127-35. [DOI: 10.1007/s00105-016-3921-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
97 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
98 Lee AM, Burns JC, Tremoulet AH. Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients. Pediatr Infect Dis J 2017;36:435-7. [PMID: 27918378 DOI: 10.1097/INF.0000000000001447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Bortlik M, Duricova D, Machkova N, Kozeluhova J, Kohout P, Hrdlicka L, Durilova M, Mitrova K, Hradsky O, Bronsky J, Malickova K, Lukas M. Impact of Anti–Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children: . Inflammatory Bowel Diseases 2014;20:495-501. [DOI: 10.1097/01.mib.0000440984.86659.4f] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 8.1] [Reference Citation Analysis]
100 Kurizky PS, Ferreira Cde C, Nogueira LS, Mota LM. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. An Bras Dermatol 2015;90:367-75. [PMID: 26131868 DOI: 10.1590/abd1806-4841.20153113] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
101 Johansen CB, Jimenez-Solem E, Haerskjold A, Sand FL, Thomsen SF. The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review. Int J Mol Sci 2018;19:E1349. [PMID: 29751529 DOI: 10.3390/ijms19051349] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
102 Nalli C, Galli J, Lini D, Merlini A, Piantoni S, Lazzaroni MG, Bitsadze V, Khizroeva J, Zatti S, Andreoli L, Fazzi E, Franceschini F, Makatsariya A, Shoenfeld Y, Tincani A. The Influence of Treatment of Inflammatory Arthritis During Pregnancy on the Long-Term Children's Outcome. Front Pharmacol 2021;12:626258. [PMID: 33815108 DOI: 10.3389/fphar.2021.626258] [Reference Citation Analysis]
103 Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response. Dig Dis Sci 2016;61:1622-7. [DOI: 10.1007/s10620-015-3992-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
104 Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstetrics & Gynecology 2015;126:401-12. [DOI: 10.1097/aog.0000000000000978] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
105 Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Digestive and Liver Disease 2013;45:787-94. [DOI: 10.1016/j.dld.2013.02.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
106 Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2020;44-45:101665. [PMID: 32359679 DOI: 10.1016/j.bpg.2019.101665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Koren G, Ornoy A. The role of the placenta in drug transport and fetal drug exposure. Expert Review of Clinical Pharmacology 2018;11:373-85. [DOI: 10.1080/17512433.2018.1425615] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
108 Sacchelli L, Magnano M, Loi C, Patrizi A, Bardazzi F. The unforeseen during biotechnological therapy for moderate-to-severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering. Dermatol Ther 2020;33:e13411. [PMID: 32291848 DOI: 10.1111/dth.13411] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
110 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 10.5] [Reference Citation Analysis]
111 Millsop JW, Heller MM, Murase JE. Safety classification systems used in dermatological medication risk counseling of pregnant and lactating patients: a case for an evidence-based approach: Safety classification systems. Dermatol Ther 2013;26:347-53. [DOI: 10.1111/dth.12015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
112 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
113 Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine 2016;83:341-3. [DOI: 10.1016/j.jbspin.2015.07.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
114 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
115 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
116 Pham-Huy A, Sadarangani M, Huang V, Ostensen M, Castillo E, Troster SM, Vaudry W, Nguyen GC, Top KA. From mother to baby: antenatal exposure to monoclonal antibody biologics. Expert Rev Clin Immunol 2019;15:221-9. [PMID: 30570400 DOI: 10.1080/1744666X.2019.1561282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
117 Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol 2019;12:1756284819852231. [PMID: 31191713 DOI: 10.1177/1756284819852231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
118 Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn’s disease. Expert Opinion on Drug Safety 2019;18:357-67. [DOI: 10.1080/14740338.2019.1612874] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
119 Biedermann L, Rogler G, Vavricka SR, Seibold F, Seirafi M. Pregnancy and breastfeeding in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:45-54. [PMID: 23051726 DOI: 10.1159/000341941] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
120 Lee KE, Jung SA, Park SH, Moon CM, Shim SY, Kim ES, Cho SJ, Kim SE, Cho KB, Yang SK. Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. Intest Res 2019;17:237-43. [PMID: 30727711 DOI: 10.5217/ir.2018.00071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
121 Vermeire S, Carbonnel F, Coulie PG, Geenen V, Hazes JM, Masson PL, De Keyser F, Louis E. Management of inflammatory bowel disease in pregnancy. J Crohns Colitis. 2012;6:811-823. [PMID: 22595185 DOI: 10.1016/j.crohns.2012.04.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
122 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
123 Hawcutt DB, Russell NJ, Maqsood H, Kouranloo K, Gomberg S, Waitt C, Sharp A, Riordan A, Turner MA. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis. Br J Clin Pharmacol 2016;82:1601-12. [PMID: 27597136 DOI: 10.1111/bcp.13067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
124 Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224. [PMID: 21157441 DOI: 10.1038/ajg.2010.464] [Cited by in Crossref: 146] [Cited by in F6Publishing: 110] [Article Influence: 13.3] [Reference Citation Analysis]
125 Croce E, Hatz C, Jonker EF, Visser L, Jaeger VK, Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports. Vaccine 2017;35:1216-26. [DOI: 10.1016/j.vaccine.2017.01.048] [Cited by in Crossref: 89] [Cited by in F6Publishing: 67] [Article Influence: 22.3] [Reference Citation Analysis]
126 Kobayashi I, Mori M, Yamaguchi K, Ito S, Iwata N, Masunaga K, Shimojo N, Ariga T, Okada K, Takei S. Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases. Modern Rheumatology 2014;25:335-43. [DOI: 10.3109/14397595.2014.969916] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
127 Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther 2017;30. [PMID: 28071837 DOI: 10.1111/dth.12454] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
128 Fischer-Betz R, Østensen M. Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients. Expert Rev Clin Pharmacol 2021;14:979-89. [PMID: 33982647 DOI: 10.1080/17512433.2021.1925536] [Reference Citation Analysis]
129 Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5:555-558. [PMID: 22115374 DOI: 10.1016/j.crohns.2011.05.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
130 Soh MC, Nelson-piercy C. High-risk pregnancy and the rheumatologist. Rheumatology 2015;54:572-87. [DOI: 10.1093/rheumatology/keu394] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 6.9] [Reference Citation Analysis]
131 Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
132 Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018;59:86-100. [PMID: 28543445 DOI: 10.1111/ajd.12641] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
133 Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 2015;13:277-89; quiz 290. [PMID: 25819232 DOI: 10.1111/ddg.12596] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
134 Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, Ozawa A, Kanekura T, Kurosawa M, Komine M, Nakajima K, Sano S, Nemoto O, Muto M, Imai Y, Yamanishi K, Aoyama Y, Iwatsuki K; The Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol 2018;45:1235-70. [DOI: 10.1111/1346-8138.14523] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 12.7] [Reference Citation Analysis]
135 Giles I, Yee C, Gordon C. Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 2019;15:391-402. [DOI: 10.1038/s41584-019-0240-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
136 Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep 2015;17:46. [PMID: 26025339 DOI: 10.1007/s11926-015-0519-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
137 Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
138 Yeung J, Gooderham MJ, Grewal P, Hong CH, Lansang P, Papp KA, Poulin Y, Turchin I, Vender R. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg 2020;24:3S-14S. [PMID: 32500730 DOI: 10.1177/1203475420928376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
139 Williams M, Chakravarty EF. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy. Curr Opin Rheumatol. 2014;26:341-346. [PMID: 24663107 DOI: 10.1097/bor.0000000000000046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
140 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
141 Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl) 2015;5:83-95. [PMID: 29387585 DOI: 10.2147/PTT.S82975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
142 Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92; quiz e24. [PMID: 23200982 DOI: 10.1016/j.cgh.2012.11.011] [Cited by in Crossref: 298] [Cited by in F6Publishing: 236] [Article Influence: 33.1] [Reference Citation Analysis]
143 Esteve-Solé A, Deyà-Martínez À, Teixidó I, Ricart E, Gompertz M, Torradeflot M, de Moner N, Gonzalez EA, Plaza-Martin AM, Yagüe J, Juan M, Alsina L. Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy. Front Immunol 2017;8:1123. [PMID: 28983301 DOI: 10.3389/fimmu.2017.01123] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
144 Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11:116-127. [PMID: 23897285 DOI: 10.1038/nrgastro.2013.135] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
145 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 15.5] [Reference Citation Analysis]
146 Singh S, Picardo S, Seow CH. Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. Clin Gastroenterol Hepatol 2020;18:1367-80. [PMID: 31712084 DOI: 10.1016/j.cgh.2019.11.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
147 Chiu M, Bao C, Sadarangani M. Dilemmas With Rotavirus Vaccine: The Neonate and Immunocompromised. Pediatric Infectious Disease Journal 2019;38:S43-6. [DOI: 10.1097/inf.0000000000002322] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
148 Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T; Committee of Survey on Infliximab use for Kawasaki disease. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan. J Pediatr 2018;195:115-120.e3. [PMID: 29224935 DOI: 10.1016/j.jpeds.2017.10.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
149 Chang J, Leong RW. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2013;14:27-36. [DOI: 10.1517/14712598.2014.853738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
150 Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GDV, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings From the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women With Autoimmune and Systemic Inflammatory Diseases: Pregnancy in Autoimmune and Systemic Inflammatory Diseases. Arthritis Care & Research 2015;67:313-25. [DOI: 10.1002/acr.22516] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
151 Vinet É, De Moura C, Pineau CA, Abrahamowicz M, Curtis JR, Bernatsky S. Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-71. [DOI: 10.1002/art.40536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
152 Campos-muñoz L, Conde-taboada A, Aleo E, Toledano E, López-bran E. Refractory pyoderma gangrenosum treated with infliximab in an infant. Clin Exp Dermatol 2014;39:336-9. [DOI: 10.1111/ced.12297] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
153 Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 2016;15:955-63. [PMID: 27490204 DOI: 10.1016/j.autrev.2016.07.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
154 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 5.7] [Reference Citation Analysis]
155 Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
156 Benchimol EI, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Jones JL. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines. Gastroenterology 2021;161:669-680.e0. [PMID: 33617891 DOI: 10.1053/j.gastro.2020.12.079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
157 Wieringa JW, Driessen GJ, Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol 2018;12:811-8. [PMID: 29972674 DOI: 10.1080/17474124.2018.1496820] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
158 Ferreira C, Azevedo A, Nogueira M, Torres T. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context 2020;9:2019-11-6. [PMID: 32201494 DOI: 10.7573/dic.2019-11-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
159 Genest G, Spitzer KA, Laskin CA. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy. J Rheumatol 2018;45:1109-15. [PMID: 29961692 DOI: 10.3899/jrheum.171152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
160 Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011;2011:287574. [PMID: 22144993 DOI: 10.1155/2011/287574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
161 Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014;20:9691-8. [PMID: 25110408 DOI: 10.3748/wjg.v20.i29.9691] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
162 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
163 Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. Journal of the American Academy of Dermatology 2011;65:870. [DOI: 10.1016/j.jaad.2011.04.030] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
164 Chiarella-Redfern H, Lee S, Jubran B, Sharifi N, Panaccione R, Constantinescu C, Benchimol EI, Seow CH. Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. Inflamm Bowel Dis 2021:izab033. [PMID: 33609034 DOI: 10.1093/ibd/izab033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016;22:213-223. [PMID: 26444103 DOI: 10.1097/mib.0000000000000596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
166 Shihab Z, Yeomans ND, De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016;10:979-988. [PMID: 26755733 DOI: 10.1093/ecco-jcc/jjv234] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
167 Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Exp Gastroenterol 2016;9:325-35. [PMID: 27789969 DOI: 10.2147/CEG.S96676] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
168 Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016;151:110-9. [DOI: 10.1053/j.gastro.2016.04.002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 138] [Article Influence: 33.2] [Reference Citation Analysis]
169 Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: Opportunities for future studies. Journal of the American Academy of Dermatology 2014;70:146-67. [DOI: 10.1016/j.jaad.2013.08.042] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 10.1] [Reference Citation Analysis]
170 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
171 Park SH, Kim HJ, Lee CK, Song EM, Kang SB, Jang BI, Kim ES, Kim KO, Lee YJ, Kim EY, Jung YJ, Park SK, Park DI, Ye BD, Jung SA, Yang SK. Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease. J Crohns Colitis 2020:jjaa099. [PMID: 32417881 DOI: 10.1093/ecco-jcc/jjaa099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
172 Marder W, Littlejohn EA, Somers EC. Pregnancy and autoimmune connective tissue diseases. Best Pract Res Clin Rheumatol 2016;30:63-80. [PMID: 27421217 DOI: 10.1016/j.berh.2016.05.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
173 Dobson R, Hellwig K. Use of disease-modifying drugs during pregnancy and breastfeeding. Curr Opin Neurol 2021;34:303-11. [PMID: 33709977 DOI: 10.1097/WCO.0000000000000922] [Reference Citation Analysis]
174 Le Jeunne C. Risques des médicaments anti-inflammatoires et immunosuppresseurs au cours de la grossesse. La Revue de Médecine Interne 2011;32:S31-5. [DOI: 10.1016/j.revmed.2011.03.332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:1329-38. [DOI: 10.1111/apt.14040] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
176 van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124. [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006] [Cited by in Crossref: 220] [Cited by in F6Publishing: 179] [Article Influence: 44.0] [Reference Citation Analysis]
177 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
178 Østensen M, Förger F. How safe are anti-rheumatic drugs during pregnancy? Current Opinion in Pharmacology 2013;13:470-5. [DOI: 10.1016/j.coph.2013.03.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
179 Dinelli MIS, Dos Santos AMN, Weckx LY, de Moraes-Pinto MI. Safe administration of rotavirus vaccine in a cohort of infants exposed to immunosuppressive drugs during gestation. Transpl Infect Dis 2018;20:e12951. [PMID: 29890028 DOI: 10.1111/tid.12951] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
180 Ye TY, Mei Y, Bao DN, Zhu YF, Xu XH, Zhu LF. Maternal anti-tumour necrosis factor-α drug use during pregnancy and risk of infection in the offspring: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1112-7. [PMID: 33376073 DOI: 10.1016/j.dld.2020.11.033] [Reference Citation Analysis]
181 Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-2602. [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
182 Truta B, Leeds IL, Canner JK, Efron JE, Fang SH, Althumari A, Safar B. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1110-7. [PMID: 31670762 DOI: 10.1093/ibd/izz250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]